A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.370 enrolled

Overview

The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

370

Conditions

Hyperlipidemia

Interventions

AtorvastatinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening * LDL-C \< 6.0 mmol/l * Triglyceride level \< 5.0 mmol/l. Exclusion Criteria: * Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.

Locations (20)

Pfizer Investigational Site

Binningen, Basel-Landschaft, Switzerland

Pfizer Investigational Site

Liestal, Basel-Landschaft, Switzerland

Outcomes

Primary Outcomes

The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Secondary Outcomes

The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.